Patents Assigned to Merck
  • PHENOXY ACETIC ACID DERIVATIVES
    Publication number: 20110288066
    Abstract: The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.
    Type: Application
    Filed: February 9, 2010
    Publication date: November 24, 2011
    Applicant: MERCK SERONO S.A.
    Inventors: Stefano Crosignani, Catherine Jorand-Lebrun, Christophe Cleva, Adeline Pretre
  • MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES
    Publication number: 20110288292
    Abstract: The present invention relates to substituted benzo[c]phenanthrene derivatives and to the production and to the use thereof in electronic devices, and to the electronic devices themselves. The present invention relates in particular to benzo[c]phenanthrene derivatives substituted with at least one aromatic unit or at least one diarylamino unit.
    Type: Application
    Filed: December 22, 2009
    Publication date: November 24, 2011
    Applicant: Merck Patent GmbH
    Inventors: Amir H. Parham, Arne Buesing, Holger Heil, Philipp Stoessel
  • PROCESS OF FORMING INSULATING LAYER BY PARTICLES HAVING LOW ENERGY
    Publication number: 20110284801
    Abstract: The invention relates to a process of preparing functional layers, like protection, encapsulation and alignment layers, on an electronic device by a low energy particle beam deposition process, to functional layers obtainable by said process, and to electronic devices comprising such functional layers.
    Type: Application
    Filed: November 18, 2009
    Publication date: November 24, 2011
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Michael Coelle, Owain Llyr Parri, David Sparrowe, Oleg Yaroshchuk, Eugene Telesh
  • 18F-LABELLED FOLATES AS PET RADIOTRACERS
    Publication number: 20110286921
    Abstract: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein fluorine-18 is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of therapy of cancer and inflammatory and autoimmune diseases.
    Type: Application
    Filed: October 12, 2009
    Publication date: November 24, 2011
    Applicant: MERCK & CIE
    Inventors: Roger Schibli, Rudolf Moser, Cristina Magdalena Muller, Simon Mensah Ametamey, Tobias Ludwig Ross, Viola Groehn
  • ORGANIC ELECTROLUMINESCENCE DEVICE
    Publication number: 20110284831
    Abstract: The present invention relates to white-emitting organic electroluminescent devices in which the dependence of the colour point on the luminance can be adjusted specifically.
    Type: Application
    Filed: February 12, 2010
    Publication date: November 24, 2011
    Applicant: MERCK PATENT GMBH
    Inventors: Joachim Kaiser, Horst Vestweber, Simone Leu
  • Triazabenzo[E]azulene derivatives for the treatment of tumors
    Patent number: 8063040
    Abstract: Novel triazabenzo[e]azulene derivatives of the formula, (I) in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of TGF-beta receptor kinase and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: September 29, 2007
    Date of Patent: November 22, 2011
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Guenter Hoelzemann, Hartmut Greiner, Christiane Amendt
  • Mineralocorticoid receptor modulators
    Patent number: 8063090
    Abstract: The present invention relates to diphenylmethyl imidazole mineralocorticoid receptor modulators compounds having the structure and their use in treating cardiovascular events.
    Type: Grant
    Filed: March 19, 2008
    Date of Patent: November 22, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Philip E. Brandish, James C. Hershey, Mark E. Fraley, Justin T. Steen
  • Renin inhibitors
    Patent number: 8063105
    Abstract: The present invention relates to novel renin inhibitors of the general Formula (I), and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds. These novel renin inhibitors are used in treating cardiovascular events and renal insufficiency.
    Type: Grant
    Filed: July 20, 2006
    Date of Patent: November 22, 2011
    Assignee: Merck Canada Inc.
    Inventors: Christopher I. Bayly, Austin C. Chen, Daniel Dube, Laurence Dube, Michel Gallant, Patrick Lacombe, Dwight MacDonald, Daniel McKay, David A. Powell, Erich L. Grimm
  • Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
    Patent number: 8063224
    Abstract: Azacycloalkane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: November 22, 2011
    Assignee: Merck Canada Inc.
    Inventors: Nicolas Lachance, Chun Sing Li, Jean-Philippe Leclerc, Yeeman K. Ramtohul
  • Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
    Patent number: 8063067
    Abstract: Compounds of the formula (I): in which R, R1, R2 and R3 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and processes for the preparation of these compounds.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: November 22, 2011
    Assignee: Merck Patent GmbH
    Inventors: Jean Jacques Zeiller, Hervè Dumas, Valérie Guyard-Dangremont, Isabelle Berard, Francis Contard, Daniel Guerrier, Gérard Ferrand, Yves Bonhomme
  • DOPED GARNET FLUORESCENT SUBSTANCE HAVING RED SHIFT FOR PC LEDS
    Publication number: 20110279022
    Abstract: The invention relates to phosphors having a garnet structure of the formula I (Ya,Lub,Sec,Tbd,The,Irf,Sbg)3?x (Al5?yMgy/2Siy/2)O12:Cex (I), where +b+c+d+e+f+g+h+i=1×=0.005 to 0.1 and y=0 to 4.0, and to a process for the preparation of these phosphors and to the use as conversion phosphors for conversion of the blue or near-UV emission from an LED.
    Type: Application
    Filed: September 2, 2009
    Publication date: November 17, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Holger Winkler, Thomas Juestel, Julian Plewa
  • N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF
    Publication number: 20110281891
    Abstract: The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.
    Type: Application
    Filed: July 28, 2011
    Publication date: November 17, 2011
    Applicant: MERCK SERONO SA
    Inventors: Dominique SWINNEN, Jerome GONZALEZ
  • PROTEIN KINASE INHIBITORS AND USE THEREOF
    Publication number: 20110282056
    Abstract: Disclosed are compounds according to Formula I: wherein the variables are described herein.
    Type: Application
    Filed: January 20, 2009
    Publication date: November 17, 2011
    Applicant: MERCK PATENT GMBH
    Inventors: Benny C. Askew, Nadia Brugger, Ruoxi Lan, Amanda E. Sutton
  • NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS
    Publication number: 20110281859
    Abstract: Compounds of the formula I, in which D, X, Y, Z, R and R1 have the meanings indicated in Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.
    Type: Application
    Filed: December 22, 2009
    Publication date: November 17, 2011
    Applicant: Merck Patent Gesellschaft MIT Beschrankter Haftung
    Inventors: Timo Heinrich, Frank Zenke, Mireille Krier, Kai Schiemann
  • Substituted indoles
    Patent number: 8058277
    Abstract: Substituted indoles of the formula (I) and physiologically acceptable derivatives and salts thereof, in which R1, D, E, R12, p, X1, E, G, X2 and Z are as defined in Claim 1, exhibit particular actions on the central nervous system, especially 5HT reuptake-inhibiting and 5 HTx-agonistic and/or -antagonistic actions and in particular serotonin-agonistic and -antagonistic properties and can be employed as antipsychotics, neuroleptics, antidepressants, anxiolyties and/or antihypertonics. They can furthermore be employed as excitatory amino acid antagonists for combating neurodegenerative diseases, including cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: November 15, 2011
    Assignee: Merck Patent GmbH
    Inventors: Oliver Schadt, Henning Böttcher, Joachim Leibrock, Kai Schiemann, Timo Heinrich, Günter Hölzemann, Christoph van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
  • Pyrrolidine derivatives as prostaglandin modulators
    Patent number: 8058305
    Abstract: Substituted pyrrolidine compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteoporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin family of compounds. In a preferred aspect, a substituted pyrrolidine compound is administered to a subject in coordination with a phosphodiesterase inhibitor compound.
    Type: Grant
    Filed: August 3, 2009
    Date of Patent: November 15, 2011
    Assignee: Merck Serono SA
    Inventors: Yihua Liao, Zhong Zhao, Gian Luca Araldi
  • Material mixtures for use in electroluminescence
    Patent number: 8058790
    Abstract: The invention relates to mixtures comprising at least one polymer, additionally comprising structural units containing at least one element from the 4th main group different from carbon and additionally comprising structural units that are triplet emissives. The inventive materials are better suited to the use in phosphorescent organic light emitting diodes than comparable prior art materials.
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: November 15, 2011
    Assignee: Merck Patent GmbH
    Inventors: Arne Buesing, René Scheurich, Susanne Heun, Ingrid Bach
  • Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
    Patent number: 8058289
    Abstract: The present invention is related to pyridine methylene azolidinone derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: November 15, 2011
    Assignee: Merck Serono SA
    Inventors: Thomas Rueckle, Anna Quattropani, Vincent Pomel, Jerome Dorbais, David Covini, Alexander Bischoff
  • Organic Electroluminescent Device
    Publication number: 20110275818
    Abstract: The present invention relates to the use of double-complex salts in electronic devices, in particular in organic electroluminescent devices, and oligomers formed from charged metal complexes.
    Type: Application
    Filed: September 25, 2009
    Publication date: November 10, 2011
    Applicant: Merck Patent GmbH
    Inventors: Hartmut Yersin, Uwe Monkowius, Tobias Fischer
  • MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES
    Publication number: 20110272685
    Abstract: The present invention describes indenofluorene derivatives containing a heteroaromatic bridge atom as a novel class of materials having emitting and hole-transporting properties, in particular for use in the emission and/or charge-transport layer of electroluminescent devices. The invention furthermore relates to a process for the preparation of the compounds according to the invention and to electronic devices comprising same.
    Type: Application
    Filed: December 22, 2009
    Publication date: November 10, 2011
    Applicant: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Christof Pflumm, Philipp Stoessel, Holger Heil, Arne Buesing